Literature DB >> 25982553

Pentraxin-3 as a local inflammatory marker in chronic spontaneous urticaria.

A Kasperska-Zajac1, A Grzanka2, M Misiolek3, B Mazur4, E Machura5.   

Abstract

BACKGROUND: The pentraxin family plays an important role in the acute phase response to immune-inflammatory processes. The short pentraxin, C-reactive protein (CRP) is a marker of chronic spontaneous urticaria (CSU) activity, reflecting the systemic effects of inflammatory mediators associated with the disease. It is known, that the long pentraxin, pentraxin 3 (PTX3) is produced at the sites of inflammation, therefore may better reflect activity of the local inflammatory processes. To assess the relevance of PTX3 in CSU patients and its association with CRP.
METHODS: Plasma PTX3 and serum CRP concentrations were measured in patients with CSU of varying severity as well as in the healthy subjects.
RESULTS: The concentrations of PTX3 and CRP were significantly increased in more severe CSU patients, when compared to mild CSU and the healthy controls. There was a significant correlation between concentrations of PTX3 and CRP.
CONCLUSIONS: In contrast to CRP, PTX3 is produced at the sites of inflammation, therefore it seems that elevated PTX3 may result from activation of cells involved in local urticarial processes. Finally, the correlation between these two pentraxins suggests that they may be upregulated by the same mechanisms associated with acute phase response in CSU.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute phase response; C reactive protein; Chronic spontaneous urticaria; Inflammation; Pentraxin 3

Mesh:

Substances:

Year:  2015        PMID: 25982553     DOI: 10.1016/j.cyto.2015.04.016

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  8 in total

1.  [Chronic spontaneous urticaria : A disease of civilization?]

Authors:  E Makrantonaki
Journal:  Hautarzt       Date:  2018-02       Impact factor: 0.751

2.  Effective treatment of different phenotypes of chronic urticaria with omalizumab: Case reports and review of literature.

Authors:  A Kasperska-Zajac; J Jarząb; A Żerdzińska; K Bąk; A Grzanka
Journal:  Int J Immunopathol Pharmacol       Date:  2016-01-04       Impact factor: 3.219

3.  The role of pentraxin 3 in pemphigus vulgaris.

Authors:  Ibrahim Halil Yavuz; Goknur Ozaydın Yavuz
Journal:  Postepy Dermatol Alergol       Date:  2019-01-11       Impact factor: 1.837

4.  Refractory chronic spontaneous urticaria and permanent atrial fibrillation associated with dental infection: Mere coincidence or something more to it?

Authors:  Alicja Kasperska-Zajac; Alicja Grzanka; Jacek Kowalczyk; Magdalena Wyszyńska-Chłap; Grażyna Lisowska; Jacek Kasperski; Jerzy Jarząb; Maciej Misiołek; Zbigniew Kalarus
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-03       Impact factor: 3.219

5.  IL-6 Transsignaling in Patients with Chronic Spontaneous Urticaria.

Authors:  Alicja Kasperska-Zajac; Alicja Grzanka; Aleksandra Damasiewicz-Bodzek
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

6.  Elevated circulating heat shock protein 70 and its antibody concentrations in chronic spontaneous urticaria.

Authors:  Alicja Kasperska-Zając; Aleksandra Damasiewicz-Bodzek; Katarzyna Bieniek; Agnieszka Skrzypulec-Frankel; Krystyna Tyrpien-Golder; Alicja Grzanka
Journal:  Int J Immunopathol Pharmacol       Date:  2017-12-22       Impact factor: 3.219

Review 7.  Mediators of Inflammation and Angiogenesis in Chronic Spontaneous Urticaria: Are They Potential Biomarkers of the Disease?

Authors:  Ilaria Puxeddu; Federico Pratesi; Domenico Ribatti; Paola Migliorini
Journal:  Mediators Inflamm       Date:  2017-09-05       Impact factor: 4.711

8.  Circulating soluble receptor for advanced glycation end products is decreased and inversely associated with acute phase response in chronic spontaneous urticaria.

Authors:  A Kasperska-Zajac; A Damasiewicz-Bodzek; K Tyrpień-Golder; J Zamlyński; A Grzanka
Journal:  Inflamm Res       Date:  2016-01-22       Impact factor: 4.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.